Monoclonal antibodies to human bladder and ureter cancers and method

• US 4,643,971 A
• Filed: 12/30/1983
• Issued: 02/17/1987
• Est. Priority Date: 03/11/1983
• Status: Expired due to Fees

• Current Assignee: Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Original Assignee: Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Inventors: Fradet, Yves, Whitemore, Willet F. Jr., Old, Lloyd J., Cordon-Cardo, Carlos, Lloyd, Kenneth O., Melamed, Myron R.
• Primary Examiner(s): Warren, Charles F.
• Assistant Examiner(s): Tarcza, John E.
• Application Number:
  US06/567,066
• Time in Patent Office: 1,145 Days
• Field of Search: 435/68, 435/172.2, 435/240, 435/241, 435/948, 436/548, 935/104, 260/112 R, 530/387
• US Class Current: 435/7.23
• CPC Class Codes: C07K 16/3038 Kidney, bladder
• CPC Class Codes: Y10S 435/948 using viruses or cell lines
• CPC Class Codes: Y10S 530/864 Monoclonal

Abstract

A panel of monoclonal antibodies, produced from human bladder tumors as immunogen, is used to diagnose the presence of transitional cell carcinoma in patients. The panel is also used to identify and differentiate low grade non-invasive papillomas from invasive life-threatening transitional cell carcinomas, thereby enabling decisions as to the extent of bladder surgery. These mAbs can also be used as a panel for tissue typing of normal and abnormal cell specimens.

Claims

1. Method for differentiating between normal and malignant human transitional bladder cells and between invasive and non-invasive bladder transitional cell carcinom as which comprises contacting a shed or intact human bladder transitional cell specimen with at least two of the monoclonal antibodies selected from the group consisting of T16, T23, T43, J233, JP165, T101, Om5, Om37, J143, T87, T138 and T110 and detecting malignant transitional bladder cells and distinguishing between invasive and non-invasive malignant transitional bladder cells reacting with said antibodies.

2. Method for differential diagnosis of malignant human bladder transitional cells which comprises contacting a shed or intact human bladder cell specimen with at least two of the monoclonal antibodies selected from the group consisting of T16, T23, T43, J233, JP165, T101, Om5, Om37, J143, T87, T138 and T110 and distinguishing invasive from non-invasive malignant transitional bladder cells and further distinguishing malignant bladder carcinoma from malignant bladder sarcoma reacting with said antibodies.

3. Method of claim 2 wherein said specimenm is separately or sequentially contacted with a panel of two or more of said monoclonal antibodies each of which is different.

4. Method of claim 2 wherein non-invasive bladder transitional cell tumors are distinguished from invasive bladder transitional cell carcinomas using monoclonal antibody selected from the group consisting of Om5, Om37 and T43.

5. Method of claim 2 wherein transitional cell bladder carcinomas are distinguished from bladder sarcomas using monoclonal antibodies selected from the group consisting of Om37, T16, T87, J143 and T43.

6. A panel of monoclonal antibodies derived from immunization with human bladder transitional cell carcinoma cells or human bladder papilloma extracts wherein said panel is capable of restricted and nonrestricted immunological reaction with, shed and intact human bladder transitional cells antigen, further capable of distinguishing invasive from non-invasive bladder transitional cell carcinoma, further capable of distinguishing human bladder transitional cell carcinoma from bladder sarcoma and wherein the panel members consist of at least two monoclonal antibodies selected from the group consisting of T16, T23, J233, JP165, T101, T43, J143, T87, T138, T101, Om37 and Om5.

7. Monoclonal antibody producing hybridoma cell lines characterized by the production of the monoclonal antibodies of the panel of claim 6.

8. Monoclonal antibodies of claim 6 recognizing human bladder transitional epithelial antigens selected from the group of glycoproteins, glycolipids and proteins.

9. Monoclonal antibodies of claim 8 wherein the glycoprotein molecular weight range is approximately 25-240 kd.

10. Monoclonal antibodies of claim 9 wherein the glycoprotein antigens are selected from the molecular weight group consisting of 48 kd, 85 kd, 60 kd, 80 kd, 30 kd, 120 kd, 25 kd, 140 kd, 240 kd.